DB18722InvestigationalCell transplant therapies
Dilanubicel consists of ex vivo expanded hematopoietic stem and progenitor cells.
- Code names
- NLA-101
Resolves to
Compound
What you can answer from here — as of April 23, 2025
Which companies are running trials of Dilanubicel, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account